Covered recipient · General Payments record
RAUL R MENA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$44.07
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $44.07 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Seagen Inc. | $22.68 | 1 |
| E.R. Squibb & Sons, L.L.C. | $21.39 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAUL R MENA
NPI 1609892256 · CMS profile ID 118905
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BURBANK, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RAUL R MENA, NPI 1609892256, CMS profile ID 118905, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $44.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.39 | 03/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932484913 | CMS |
| Seagen Inc. | $22.68 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904116569 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2021 , PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $175.09 | 1 |
| PY2024 | Principal investigator | $3,280.00 | 3 |
| PY2023 | Principal investigator | $10,185.60 | 2 |
| PY2022 | Recipient | $6,880.00 | 1 |
| PY2022 | Principal investigator | $325,752.17 | 18 |
| PY2021 | Recipient | $18.75 | 1 |
| PY2021 | Principal investigator | $395,903.61 | 24 |
| PY2020 | Recipient | $1,784.80 | 2 |
| PY2020 | Principal investigator | $859,478.43 | 105 |
| PY2019 | Recipient | $4,319.40 | 2 |
| PY2019 | Principal investigator | $2,023,210.35 | 60 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca UK Limited | $31.64 | 12/31/2019 | Non-covered Recipient Entity Innovative Clinical Research Institute | A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | No dispute reported | 06/30/2026 | 685000353 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 12/26/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689414609 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 12/03/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689414329 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 11/29/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 | No dispute reported | 06/30/2026 | 691511237 |
| Principal investigator 1 | TESARO, Inc. | $53,524.80 | 11/21/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689414219 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $333.45 | 11/20/2019 | Non-covered Recipient Entity Providence Health System Southern Ca | PCYC-1145-LT | No dispute reported | 06/30/2026 | 673114813 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 11/11/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 | No dispute reported | 06/30/2026 | 691517729 |
| Principal investigator 1 | TESARO, Inc. | $40,143.60 | 11/06/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689414039 |
| Principal investigator 1 | TESARO, Inc. | $26,762.40 | 10/30/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689413879 |
| Principal investigator 1 | TESARO, Inc. | $40,404.86 | 10/17/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689413651 |
| Principal investigator 1 | TESARO, Inc. | $28,747.80 | 10/17/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689413657 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 10/07/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689413425 |
| Principal investigator 1 | TESARO, Inc. | $53,524.80 | 09/19/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689413131 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $421.02 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer | No dispute reported | 06/30/2026 | 691431733 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC | No dispute reported | 06/30/2026 | 691458371 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $338.22 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC | No dispute reported | 06/30/2026 | 691458375 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $400.26 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC | No dispute reported | 06/30/2026 | 691458379 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer | No dispute reported | 06/30/2026 | 691461439 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $462.48 | 09/13/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer | No dispute reported | 06/30/2026 | 691461619 |
| Principal investigator 1 | TESARO, Inc. | $40,143.60 | 09/03/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412955 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,514.53 | 08/27/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC | No dispute reported | 06/30/2026 | 691361599 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,113.55 | 08/27/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 | No dispute reported | 06/30/2026 | 691390913 |
| Principal investigator 1 | TESARO, Inc. | $93,668.40 | 08/14/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412651 |
| Principal investigator 1 | TESARO, Inc. | $9,360.00 | 08/13/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | No dispute reported | 06/30/2026 | 689412647 |
| Principal investigator 1 | TESARO, Inc. | $22,360.50 | 08/08/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412553 |
| Principal investigator 1 | TESARO, Inc. | $25,807.00 | 08/06/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412493 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $213.00 | 07/24/2019 | Non-covered Recipient Entity DISNEY FAMILY CANCER CENTER | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer | No dispute reported | 06/30/2026 | 691371611 |
| Principal investigator 1 | TESARO, Inc. | $53,873.14 | 07/16/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412209 |
| Principal investigator 1 | TESARO, Inc. | $10,854.90 | 07/16/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412235 |
| Principal investigator 1 | TESARO, Inc. | $9,304.20 | 07/16/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412259 |
| Principal investigator 1 | TESARO, Inc. | $80,673.34 | 07/16/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412271 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 07/11/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689412159 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15,568.00 | 06/26/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 | No dispute reported | 06/30/2026 | 691360025 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 06/18/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411759 |
| Principal investigator 1 | TESARO, Inc. | $33,800.40 | 06/11/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411709 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 05/30/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411599 |
| Principal investigator 1 | TESARO, Inc. | $138,826.94 | 05/14/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411319 |
| Principal investigator 1 | TESARO, Inc. | $74,593.58 | 05/10/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411219 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 05/08/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689411199 |
| Principal investigator 1 | Eli Lilly and Company | $14,624.00 | 04/29/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A PHASE 2 STUDY OF LY2784544 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS | No dispute reported | 06/30/2026 | 654292419 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 04/23/2019 | Non-covered Recipient Entity UNAVAILABLE | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 | No dispute reported | 06/30/2026 | 691386015 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 04/17/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410911 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $333.45 | 04/12/2019 | Non-covered Recipient Entity Providence Health System Southern Ca | PCYC-1145-LT | No dispute reported | 06/30/2026 | 673113037 |
| Principal investigator 1 | PFIZER INC. | $14,400.00 | 04/04/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEMSOUTHERN CALIFORNIA | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 671627611 |
| Principal investigator 1 | TESARO, Inc. | $53,524.80 | 04/04/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410771 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $230.40 | 03/25/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 | No dispute reported | 06/30/2026 | 691342871 |
| Principal investigator 1 | TESARO, Inc. | $13,682.00 | 03/19/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410481 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 03/06/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410361 |
| Principal investigator 1 | TESARO, Inc. | $23,654.70 | 02/14/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410073 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 02/14/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410151 |
| Principal investigator 1 | Eli Lilly and Company | $23,674.00 | 02/12/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654297191 |
| Principal investigator 1 | TESARO, Inc. | $51,801.10 | 02/12/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689410005 |
| Principal investigator 1 | Genentech, Inc. | $31,149.00 | 02/05/2019 | Non-covered Recipient Entity PROVIDENCE TARZANA MEDICAL CENTER | PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC | No dispute reported | 06/30/2026 | 681086513 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 01/29/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689409897 |
| Recipient | Eli Lilly and Company | $489.40 | 01/28/2019 | Covered Recipient Physician | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654283541 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15,805.00 | 01/17/2019 | Non-covered Recipient Entity UNAVAILABLE | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 | No dispute reported | 06/30/2026 | 691308935 |
| Recipient | Eli Lilly and Company | $3,830.00 | 01/15/2019 | Covered Recipient Physician | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654283539 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $333.45 | 01/11/2019 | Non-covered Recipient Entity Providence Health System Southern Ca | PCYC-1145-LT | No dispute reported | 06/30/2026 | 673112939 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,500.00 | 01/09/2019 | Non-covered Recipient Entity Providence Little Company Of Mary Medical Center Torrance | An Open Label Non randomized Prospective Biomarker Study to Assess Analytic Concordance Between Non invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non small Cell Lung Cancer | No dispute reported | 06/30/2026 | 684989107 |
| Principal investigator 1 | TESARO, Inc. | $66,906.00 | 01/09/2019 | Non-covered Recipient Entity PROVIDENCE SAINT JOSEPH MEDICAL CENTER | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689409569 |
| Principal investigator 1 | TESARO, Inc. | $36,659.24 | 01/08/2019 | Non-covered Recipient Entity PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | No dispute reported | 06/30/2026 | 689409477 |
| Principal investigator 1 | AstraZeneca UK Limited | $1,000.00 | 01/07/2019 | Non-covered Recipient Entity Innovative Clinical Research Institute | A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | No dispute reported | 06/30/2026 | 685000345 |